Vasken Dilsizian, MD, has been a professor of radiology and medicine at the University of Maryland School of Medicine since 2001, and chief of the division of nuclear medicine at the University of Maryland Medical Center in Baltimore since 2007.
He graduated from Tufts University School of Medicine in 1982. This was followed by Internal Medicine residency at Georgetown University School of Medicine in 1985, Fellowship in Cardiology at Boston University Medical Center and Massachusetts General Hospitals in 1988, and Nuclear Medicine residency at the National Institutes of Health in 1992. He holds a master's and bachelor's degrees in chemical engineering, both from Tufts University. He is a Diplomate of the American Board of Internal Medicine, Cardiovascular Diseases, and Nuclear Medicine.
Dilsizian has been involved in many councils, committees, and task forces of the American College of Cardiology, American Heart Association, American Society of Nuclear Cardiology and the Society of Nuclear Medicine and Molecular Imaging. Currently, he is the President of the Cardiovascular Council and Director-at-Large of the SNMMI House of Delegates. He also serves as the Chair of the ACC Task Force on clinical competence and training in nuclear cardiology (COCATS 4) and Special Government Employee (SGE) for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the FDA. He was recently selected to serve as the Nuclear Cardiologist for the Nuclear Regulatory Commission (NRC) Advisory Committee on the Medical Uses of Isotopes (ACMUI) for a four year term, starting March 1, 2014.
He spent 13 years at the National Institutes of Health, where he served as the Director of Nuclear Cardiology from 1992 to 2001. His research efforts over the past 25 years have culminated into 172 original, peer-reviewed manuscripts and invited editorials/articles, 9 books, and 34 book chapters. He has served as a Guest Editor on 5 periodicals and excerpts. He serves as a Guest Editor for Circulation and the Journal of Nuclear Cardiology, Associate Editor of the Journal of American College of Cardiology - Cardiovascular Imaging, and Editor-in-Chief of Current Cardiovascular Imaging Reports. He was recently appointed to serve as the Section Editor for the area of Imaging of the Journal of the American College of Cardiology. He is a co-editor of the “Atlas of Nuclear Cardiology” (now in its 4th edition), and “Cardiac CT, PET and MR” (now in its 2nd edition). He is also a co-author of the “Nuclear Cardiology” chapter in Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine.
Internal Medicine, Cardiovascular Diseases, Nuclear Medicine
Lab Techniques and Equipment:
SPECT, PET, Hybrid PET/CT
Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990; 323:141-146.
Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with coronary artery disease and left ventricular dysfunction: Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 1991; 83:26-37.
Dilsizian V, Smeltzer WR, Freedman NMT, Dextras R, Bonow RO. Thallium reinjection after stress-redistribution imaging: Does 24 hour delayed imaging following reinjection enhance detection of viable myocardium? Circulation 1991; 83:1247-1255.
Cannon RO, Dilsizian V, O'Gara, PT, Udelson JE, Schenke WH, Quyyumi A, Fananapazir L, Bonow RO. Myocardial metabolic, hemodynamic and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991; 83:1660-1667.
Dilsizian V, Freedman NMT, Bacharach SL, Perrone-Filardi P, Bonow RO. Regional thallium uptake in irreversible defects: Magnitude of change in thallium activity after reinjection distinguishes viable from nonviable myocardium. Circulation 1992; 85:627-634.
Dilsizian V and Bonow RO. Differential uptake and apparent thallium-201 "washout" after thallium reinjection: Options regarding early redistribution imaging before reinjection or late redistribution imaging after reinjection. Circulation 1992; 85:1032-1038.
Cannon RO, Dilsizian V, O'Gara PT, Udelson JE, Tucker E, Panza J, Fananapazir L, McIntosh CL, Wallace RB, Bonow RO. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 1992; 85:1039-1045.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22:796-804.
Dilsizian V, Perrone-Filardi P, Arrighi JA, Bacharach SL, Quyyumi AA, Freedman NMT, Bonow RO. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium: Comparison with metabolic activity by PET. Circulation 1993; 88:941-952.
Dilsizian V, Arrighi JA, Diodati JG, Quyyumi AA, Bacharach SL, Alavi K, Marin-Neto JA, Katsiyiannis PT, Bonow RO. Myocardial viability in patients with chronic coronary artery disease: comparison of 99mTc-sestamibi with thallium reinjection and 18F-fluorodeoxyglucose. Circulation 1994; 89:578-587.
Arrighi JA, Dilsizian V, Perrone-Filardi P, Diodati JG, Bacharach SL, Bonow RO. Improvement of the age-related impairment in left ventricular diastolic filling with verapamil in the normal human heart. Circulation 1994; 90:213-219.
Panza JA, Dilsizian V, Laurienzo JM, Curiel RV, Katsiyiannis PT. Relation between thallium uptake and contractile response to dobutamine: implications regarding myocardial viability in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1995; 91:990-998
Dilsizian V. Myocardial viability: Contractile reserve or cell membrane integrity? J Am Coll Cardiol 1996; 28:443-446
Srinivasan G, Kitsiou AN, Bacharach SL, Bartlett ML, Miller-Davis C, Dilsizian V. 18F-fluorodeoxyglucose Single Photon Emission Computed Tomography: Can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998; 97:843-850.
Kitsiou AN, Srinivasan G, Quyyumi AA, Summers RM, Bacharach SL, Dilsizian V. Stress-induced reversible and mild-to-moderate irreversible thallium defects: Are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation 1998; 98:501-508
Kitsiou AN, Bacharach SL, Bartlett ML, Srinivasan G, Summers RM, Quyyumi AA, Dilsizian V. 13N-Ammonia myocardial blood flow and uptake: Relation to functional outcome of asynergic regions after revascularization. J Am Coll Cardiol 1999; 33:678-686.
Udelson JE, Dilsizian V, Laham RJ, Chronos N, VanSant J, Galt JR, Pike M, Yoshigawa C, Simons M. Therapeutic angiogenesis and recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-1610.
Shirani J, Lee J, Quigg RJ, Pick R, Bacharach SL, Dilsizian V. Relation of thallium uptake to morphologic features of chronic ischemic heart disease: evidence for myocardial remodeling in non-infarct myocardium. J Am Coll Cardiol 2001;38:84-90.
Bennett SK, Smith MF, Gottlieb SS, Fisher ML, Bacharach SL, Dilsizian V. Effect of Metoprolol on absolute myocardial blood flow in patients with heart failure secondary to ischemic or non-ischemic cardiomyopathy. Am J Cardiol 2002;89:1431-1434.
Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan TJ, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. AHA Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Circulation 2002;105:539-542.
Udelson JE, Heller GV, Wackers FJ, Chai A, Hinchman D, Coleman P, Dilsizian V, DiCarli M, Hachamovitch R, Johnson JR, Barrett RJ, Gibbons RJ. A randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist Binodenoson for pharmacologic stress as an adjunct to myocardial perfusion imaging. Circulation 2004;109:457-64.
Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, Binkley P, Buchele D, Anand I, Swingen C, DiCarli MF, Thomas JD, Jaber WA, Opie SR, Campbell A, McCarthy P, Yeager M, Dilsizian V, Griffith BP, Korn R, Kreuger SK, Ghazoul M, MacLellan WR, Fonarow G, Eisen HJ, Dinsmore J, Diethrich E. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: Four-year follow-up. Circulation 2005;112:1748-1755.
Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram M, Goodbody AE, Babich JW, Udelson JE. Metabolic imaging with β-methyl-β²-[123I]-iodophenyl-pentadecanoic acid (BMIPP) identifies ischemic memory following demand ischemia. Circulation 2005;112(14):2169--2174.
Dilsizian V, Eckelman WC, Loredo ML, Jagoda EM, Shirani J. Evidence for tissue angiotensin-converting-enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J Nucl Med 2007;48:182-187.
Dilsizian V, Fink J. Deleterious Effect of Altered Myocardial Fatty Acid Metabolism in Kidney Disease. J Am Coll Cardiol 2008; 51(2): 146-8.
Dilsizian V. FDG Uptake as a Surrogate Marker for Antecedent Ischemia, J Nucl Med 2008; 49 (12):1909-11.
Dilsizian V, Narula J. Qualitative and Quantitative Scrutiny by Regulatory Process: Is the Truth Subjective or Objective? J Am Coll Cardiol Img 2009; 2:1037-8.
Dilsizian V, Bacharach SL, Beanlands SR, Bergmann SR, Delbeke D, Fischman AJ, Gropler RJ, Knuuti J, Schelbert H, Travin M.. PET Myocardial Perfusion and Metabolism Clinical Imaging J Nucl Card 2009; 16 (4):651 ISSN 1532-6551 (Online) doi: 10.1007/s12350-009-9094-9.
Dickfeld T, Lei P, Dilsizian V, Jeudy J, Nader A, Dong J, Peters R, Saba M, Shevkar R, Shorofsky S. Integration of three-dimensional scar maps for ventricular tachycardia ablation with positron emission tomography-computed tomography. J Am Coll Cardiol Img 2008; 1:73-82.
Shirani J and Dilsizian V. Imaging Left Ventricular Remodeling: Targeting the Neurohumoral Axis. Nat Clin Pract Card 2008; 5: S57-62.
Taegtmeyer H and Dilsizian V. Imaging Myocardial Metabolism and Ischemic Memory. Nat Clin Pract Card 2008; 5:S42-48.
Laskey WK, Feinendegen LE, Neumann RD, Dilsizian V. Low-Level Ionizing Radiation from Non-invasive Cardiac Imaging: Can we Extrapolate Estimated Risks from Epidemiologic Data to the Clinical Setting? J Am Coll Cardiol Img 2010;3:517-24.
Schindler TH, Quercioli A, Schelbert HR, Dilsizian V. Cardiac PET Imaging for the Detection and Monitoring of Coronary Artery Disease and Microvascular Health. J Am Coll Cardiol Img 2010; 3:623-40.
Kontos MC, Dilsizian V, Weiland F, DePuey G, Mahmarian JJ, Iskandrian AE, Bateman T, Heller GV, Ananthasubramaniam K, Li Y, Goldman JL, Armor T, Kacena KA, LaFrance ND, Garcia EV, Babich JW, Udelson JE. Iodofiltic Acid I 123 (BMIPP) Fatty Acid Imaging Improves Initial Diagnosis in Emergency Department Patients with Suspected Acute Coronary Syndromes: A Multicenter Trial. J Am Coll Cardiol 2010; 56:290-99.
Fink JC, Lodge MA, Smith MF, Hinduja A, Brown J, Dinits-Pensy MY, Dilsizian V. Pre-Clinical Myocardial Metabolic Alterations in Chronic Kidney Disease. Cardiology 2010 116(3):160-167.
Buxton DB, Antman M, Danthi N, Dilsizian V, Fayad ZA Garcia MJ, Jaff MR, Klimas M, Libby P, Nahrendorf M, Sinusas AJ, Wickline SA, Wu JC, Bonow RO, Weissleder R. Report of the National Heart, Lung, and Blood Institute Working Group on the Translation of Cardiovascular Molecular Imaging Circulation 2011;123:2157-63.
Osterholt M, Sen S, Dilsizian V, Taegtmeyer H. Targeted Metabolic Imaging to Improve the Management of Heart Disease. J Am Coll Cardiol Img 2012; 5:214-26
Dilsizian V, Zynda TK, Petrov A, Ohshima S, Tahara N, Haider N, Donohue A, Aras O, Fernia F, Hillier S, Joyal J, Wong ND, Coleman T, Babich J, Narula J. Molecular Imaging of Human ACE-1 Expression in Transgenic Rats. J Am Coll Cardiol Img 2012; 5:409-18.
Tian J, Smith M, Ahmad G, Dilsizian V, Jimenez A, Dickfeld T. Integration of Three Dimensional Scar Maps using Single Photon Emission Computed Tomography to Guide Ventricular Tachycardia Ablation. J Nucl Med 2012; 53:894-901.
Schindler TH and Dilsizian V. Cardiac Positron Emission Tomography/Computed Tomography Imaging of the Renin-Angiotensin System in Humans Holds Promise for Image-Guided Approach to Heart Failure Therapy. J Am Coll Cardiol 2012; 5(12):1269-84.
Dilsizian V, Taillefer R. Journey in Evolution of Nuclear Cardiology: Will There be Another Quantum Leap with the F-18 labeled Myocardial Perfusion Tracers? J Am Coll Cardiol Img 2012;5:1269-84.
Dilsizian V, Achenbach S, Narula J. On Adding Versus Selecting Imaging Modalities for Incremental Diagnosis: A Case-Study of 18F-Fluorodeoxyglucose PET/CT in Prosthetic Valve Endocarditis. J Am Coll Cardiol Img 2013; 6:1020-1.
Chen W and Dilsizian V. Targeted PET/CT Imaging of Vulnerable Atherosclerotic Plaques: Microcalcification with Sodium Fluoride and Inflammation with Fluorodeoxyglucose. Curr Cardiol Rep 2013; June;15(6);364.
Shirani J, Dilsizian V. Novel Molecular Angiotensin Converting Enzyme and Angiotensin Receptor Imaging Techniques. Curr Cardiol Rep 2014;16:466.
Faculty members: Update your contact information and create a profile.